🇺🇸 FDA

Intelligence · Patent portfolio

NORTHWEST BIOTHERAPEUTICS Patents

Full USPTO pharma patent portfolio for NORTHWEST BIOTHERAPEUTICS — grant dates, expiration, and drug cross-links.

Patents
595
Expiring ≤24m
13

Quick answer

NORTHWEST BIOTHERAPEUTICS has 595 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 13 expire within 24 months — use filters for patent-cliff planning.

Page 5 of 13

  1. US 10822301

    3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10800753

    Tetrahydrothiophene-based GABA aminotransferase inactivators and analogs thereof for treating neurological disorders

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10799475

    Substituted phenyl aziridine precursor analogs for inhibiting androgen-independent prostate cancer cell growth

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10799520

    Lipotechoic acid for immune modulation

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10799604

    Biopolymer-nanoparticle composite implant for tumor cell tracking

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10799593

    Nanodiamond particle complexes

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10792327

    Supramolecular gylcosaminoglycans

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10792251

    Liposomal particles, methods of making same and uses thereof

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10786582

    Gd(III)-dithiolane gold nanoparticle conjugates

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10780067

    Endoxifen for local transdermal therapy to the breast

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10780076

    Inhibition of cancer cell motility

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10765687

    Methods and compounds to inhibit enveloped virus release

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10759791

    Mammalian and bacterial nitric oxide synthase inhibitors

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10750943

    Imaging-guided creating and monitoring of retinal vascular occlusive disease

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10751317

    Methods and compositions for increasing the potency of antifungal agents

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10752656

    Anti-microbial supramolecular structures

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10736915

    Nylon-3 co-polymers and synthetic lung surfactant compositions containing same

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10731131

    Dendritic cell generator

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10723702

    Photocrosslinking reagents and methods of use thereof

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10716758

    Liposomal statin formulation

    Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10689357

    N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10688195

    Polymyxin B-coated nanoparticles

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10683272

    Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10653782

    Retroviral particles expressing Sirt1 embedded within PPCN

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10633493

    Facile assembly of soft nanoarchitectures and co-loading of hydrophilic and hydrophobic molecules via flash nanoprecipitation

    Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10632088

    Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria

    Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10624849

    Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites

    Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10617747

    Peptide conjugated particles

    Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10590414

    Brush polymer-assisted compaction of oligonucleotides

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10583199

    Nanocarriers having surface conjugated peptides and uses thereof for sustained local release of drugs

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10584389

    Cancer screening by detection of ultrastructural and molecular markers

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10568898

    Lipophilic nanoparticles for drug delivery

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10570185

    Method to detect autoantibody reactivity for deamidated insulin autoantigen in diabetes

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10561761

    Polymer metal-organic framework composites

    Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10548856

    Compounds and methods for modulating serotonin receptors in the periphery

    Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10538570

    Targeted and modular exosome loading system

    Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10525086

    Methods for growth and maturation of ovarian follicles

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10517924

    High density lipoprotein nanoparticles for inflammation

    Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10501435

    Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10500156

    Multi-compartmental macrophage delivery

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10500218

    Uptake of pharmaceuticals within cyclodextrin-based porous materials

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10479980

    Artificial ovary

    Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10466259

    Synthetic antigen compositions for detecting anti-phosphatidylethanolamine antibodies

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10463745

    Materials for tissue regeneration

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10443049

    Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)

    Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10442812

    Substituted 4-methyl-pyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity

    Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10435375

    CXCR4 chemokine receptor modulators

    Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10434225

    Para-xylene films and therapeutic uses thereof

    Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does NORTHWEST BIOTHERAPEUTICS have?

595 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do NORTHWEST BIOTHERAPEUTICS patents expire?

13 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.